UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):May 24, 2017
Repros Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware (State or Other Jurisdiction of Incorporation) | 001-15281 (Commission File Number) | 76-0233274 (I.R.S. Employer Identification No.) |
| 2408 Timberloch Place, Suite B-7 | | |
| The Woodlands, TX | | 77380 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(281) 719-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined inRule 405of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 24, 2017, Jaye Thompson, Ph.D., Senior Vice President of Clinical and Regulatory of Repros Therapeutics Inc. (the “Company”), separated from the Company, effective May 24, 2017. Dr. Thompson is expected to enter into a separation agreement with the Company in the near future that will provide for a severance payment consisting of six and one-half months of salary and the continuation of Company-paid benefits for a six month period, as well as providing for Dr. Thompson to have two years to exercise her vested stock options outstanding as of her retirement. The separation agreement is also expected to provide that Dr. Thompson is bound by certain restrictive covenants, including non-compete and non-solicitation provisions, and to contain a release by Dr. Thompson of all claims against the Company, subject to certain enumerated exceptions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | REPROS THERAPEUTICS INC. | |
| | | | |
| | | | |
| | | | |
| | By: | /s/ Kathi Anderson | |
| | | Kathi Anderson | |
| | | CFO | |
Dated: May 31, 2017
